Edwards Lifesciences Corp (EW) Holdings Trimmed by Greenleaf Trust

Greenleaf Trust trimmed its holdings in Edwards Lifesciences Corp (NYSE:EW) by 2.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 60,812 shares of the medical research company’s stock after selling 1,820 shares during the quarter. Edwards Lifesciences makes up approximately 0.2% of Greenleaf Trust’s portfolio, making the stock its 25th largest holding. Greenleaf Trust’s holdings in Edwards Lifesciences were worth $10,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. LFA Lugano Financial Advisors SA bought a new position in Edwards Lifesciences in the 3rd quarter worth approximately $121,000. Private Capital Group LLC bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $112,000. Centaurus Financial Inc. bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $114,000. Signet Financial Management LLC bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $136,000. Finally, Ropes Wealth Advisors LLC boosted its position in shares of Edwards Lifesciences by 187.4% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 1,006 shares of the medical research company’s stock valued at $146,000 after acquiring an additional 656 shares during the last quarter. Institutional investors and hedge funds own 82.63% of the company’s stock.

Shares of EW opened at $139.22 on Tuesday. The firm has a market capitalization of $29.34 billion, a P/E ratio of 36.64, a P/E/G ratio of 1.84 and a beta of 0.56. Edwards Lifesciences Corp has a 52-week low of $100.20 and a 52-week high of $175.00. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.05. The company had revenue of $906.60 million during the quarter, compared to the consensus estimate of $927.56 million. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. Edwards Lifesciences’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the company earned $0.84 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.69 earnings per share for the current fiscal year.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,500 shares of the stock in a transaction on Wednesday, October 10th. The stock was sold at an average price of $147.50, for a total value of $811,250.00. Following the sale, the vice president now owns 25,490 shares in the company, valued at $3,759,775. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 700 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $142.64, for a total value of $99,848.00. Following the completion of the sale, the vice president now owns 27,772 shares in the company, valued at approximately $3,961,398.08. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 120,311 shares of company stock valued at $17,238,991. 1.84% of the stock is owned by corporate insiders.

EW has been the subject of a number of research reports. BMO Capital Markets increased their target price on Edwards Lifesciences to $162.00 and gave the company an “outperform” rating in a research report on Tuesday, July 10th. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Saturday, July 14th. Northland Securities reiterated a “hold” rating and set a $120.00 target price on shares of Edwards Lifesciences in a research report on Friday, July 27th. Jefferies Financial Group reiterated a “buy” rating and set a $168.00 target price on shares of Edwards Lifesciences in a research report on Friday, July 27th. Finally, JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $133.00 to $150.00 and gave the company a “neutral” rating in a research report on Friday, July 27th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. Edwards Lifesciences has a consensus rating of “Buy” and an average price target of $156.79.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply